Aktie A2PURU SINOMAB BIOSCIENCE LIMITED
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen SinoMab BioScience Limited

Aktien

A2PURU

HK0000544194

3681

Verzögert Hong Kong S.E.
Andere Börsenplätze
 04:11:18 09.05.2024 		% 5 Tage % 1. Jan.
1,88 HKD +3,30 % Intraday Chart für SinoMab BioScience Limited -1,05 % +11,90 %
25.03. SinoMab BioScience Limited berichtet über die Ergebnisse für das am 31. Dezember 2023 endende Geschäftsjahr CI
07.02. SinoMab BioScience Limited ernennt Shanchun Wang zum geschäftsführenden Direktor CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
SinoMab BioScience preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy
SinoMab BioScience Limited Reports Earnings Results for the Full Year Ended December 31, 2023
SinoMab BioScience Limited Appoints Shanchun Wang as an Executive Director
SinoMab BioScience Raises HK$62.2 Million from Thirteen Share Subscriptions
SinoMab BioScience Issues 56.8 Million Shares to 15 Investors
SinoMab Doses First Batch of Subjects in Phase 1 Trial of Atopic Dermatitis Drug in China
SinoMab Bioscience Limited Announces First Cohort of the Health Subsidiaries Dosed in A Phase I Clinical Trial of SM17 in China
China Accepts Clinical Trial Application for SinoMab BioScience's Alzheimer's Treatment; Shares Rise 3%
Sinomab Bioscience Limited Announces IND Application for SM03 (Suciraslimab) for the Treatment of Alzheimer's Disease Accepted by NMPA CDE
China Accepts New Drug Application of SinoMab's Dermatitis Medication; Shares Rise 3%
SinoMab's IND Application of SM17 has once again Received Approval from NAMP
Sinomab Bioscience Limited announces Change of Non-Executive Directors
Chinese Regulator Accepts License Application for SinoMab's Arthritis Drug
China Accepts SinoMab's Biologics License Application for Arthritis Treatment
SinoMab BioScience Limited Announces National Medical Products Administration Accepts Biologics License Application for SM03 in the Treatment of Rheumatoid Arthritis
SinoMab Bioscience to Shrink Loss in H1
SinoMab BioScience Limited Reports Earnings Results for the Half Year Ended June 30, 2023
SinoMab Bioscience Obtains Clinical Trial Approval in China for Asthma Drug
SinoMab Announces that IND Application of SM17 for the Treatment of Asthma was Approved by NAMP
Sinomab Bioscience Limited Announces IND Approval for Sm17 by Nmpa
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2PURU Aktie
  4. Nachrichten SinoMab BioScience Limited
  5. Andere Sprachen